These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

95 related items for PubMed ID: 18248963

  • 1. The impact of multidrug resistance on the pathogenicity of Escherichia coli: an experimental study.
    Bristianou M, Panagou C, Adamis T, Raftogiannis M, Antonopoulou A, Chrisofos M, Galani I, Kanellakopoulou K, Tsaganos T, Giamarellos-Bourboulis EJ.
    Int J Antimicrob Agents; 2008 Mar; 31(3):216-23. PubMed ID: 18248963
    [Abstract] [Full Text] [Related]

  • 2. Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae.
    Giamarellos-Bourboulis EJ, Tziortzioti V, Koutoukas P, Baziaka F, Raftogiannis M, Antonopoulou A, Adamis T, Sabracos L, Giamarellou H.
    J Antimicrob Chemother; 2006 May; 57(5):937-44. PubMed ID: 16549515
    [Abstract] [Full Text] [Related]

  • 3. Impact of multidrug resistance on experimental empyema by Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ, Tzepi I, Tsovolou I, Spyridaki A, Tsaganos T, Vaki I, Kotsaki A, Polychronopoulos V.
    Respiration; 2011 May; 82(1):46-53. PubMed ID: 21525725
    [Abstract] [Full Text] [Related]

  • 4. Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli.
    Giamarellos-Bourboulis E, Adamis T, Sabracos L, Raftogiannis M, Baziaka F, Tsaganos T, Koutoukas P, Plachouras D, Karayannacos P, Giamarellou H.
    Scand J Infect Dis; 2005 May; 37(1):48-54. PubMed ID: 15764190
    [Abstract] [Full Text] [Related]

  • 5. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ, Antonopoulou A, Raftogiannis M, Koutoukas P, Tsaganos T, Tziortzioti V, Panagou C, Adamis T, Giamarellou H.
    BMC Infect Dis; 2006 Feb 21; 6():31. PubMed ID: 16504031
    [Abstract] [Full Text] [Related]

  • 6. Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli.
    Giamarellos-Bourboulis EJ, Baziaka F, Antonopoulou A, Koutoukas P, Kousoulas V, Sabracos L, Panagou C, Perrea D, Giamarellou H.
    Int J Antimicrob Agents; 2005 Feb 21; 25(2):168-72. PubMed ID: 15664488
    [Abstract] [Full Text] [Related]

  • 7. Local production of inflammatory mediators in an experimental model of acute obstructive pyelonephritis.
    Kaboré AF, Simard M, Bergeron MG.
    J Infect Dis; 1999 May 21; 179(5):1162-72. PubMed ID: 10191219
    [Abstract] [Full Text] [Related]

  • 8. Nursing homes as a reservoir of extended-spectrum beta-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli.
    Rooney PJ, O'Leary MC, Loughrey AC, McCalmont M, Smyth B, Donaghy P, Badri M, Woodford N, Karisik E, Livermore DM.
    J Antimicrob Chemother; 2009 Sep 21; 64(3):635-41. PubMed ID: 19549667
    [Abstract] [Full Text] [Related]

  • 9. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival.
    Giamarellos-Bourboulis EJ, Papadimitriou E, Galanakis N, Antonopoulou A, Tsaganos T, Kanellakopoulou K, Giamarellou H.
    Int J Antimicrob Agents; 2006 Jun 21; 27(6):476-81. PubMed ID: 16707252
    [Abstract] [Full Text] [Related]

  • 10. Cytokine expression in response to bacterial antigens in preterm and term infant cord blood monocytes.
    Tatad AM, Nesin M, Peoples J, Cheung S, Lin H, Sison C, Perlman J, Cunningham-Rundles S.
    Neonatology; 2008 Jun 21; 94(1):8-15. PubMed ID: 18097152
    [Abstract] [Full Text] [Related]

  • 11. Analysis of plasmid-mediated multidrug resistance in Escherichia coli and Klebsiella oxytoca isolates from clinical specimens in Japan.
    Ode T, Saito R, Kumita W, Sato K, Okugawa S, Moriya K, Koike K, Okamura N.
    Int J Antimicrob Agents; 2009 Oct 21; 34(4):347-50. PubMed ID: 19560903
    [Abstract] [Full Text] [Related]

  • 12. Experimental sepsis using Pseudomonas aeruginosa: the significance of multi-drug resistance.
    Giamarellos-Bourboulis EJ, Koussoulas V, Panagou C, Adamis T, Baziaka F, Skiadas I, Perrea D, Dionyssiou-Asteriou A, Giamarellou H.
    Int J Antimicrob Agents; 2004 Oct 21; 24(4):357-61. PubMed ID: 15380261
    [Abstract] [Full Text] [Related]

  • 13. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
    Zhanel GG, Baudry PJ, Tailor F, Cox L, Hoban DJ, Karlowsky JA.
    J Antimicrob Chemother; 2009 Oct 21; 64(4):824-8. PubMed ID: 19643776
    [Abstract] [Full Text] [Related]

  • 14. Early apoptosis of blood monocytes is a determinant of survival in experimental sepsis by multi-drug-resistant Pseudomonas aeruginosa.
    Antonopoulou A, Raftogiannis M, Giamarellos-Bourboulis EJ, Koutoukas P, Sabracos L, Mouktaroudi M, Adamis T, Tzepi I, Giamarellou H, Douzinas EE.
    Clin Exp Immunol; 2007 Jul 21; 149(1):103-8. PubMed ID: 17488299
    [Abstract] [Full Text] [Related]

  • 15. Anti-L-selectin antibody therapy does not worsen the postseptic course in a baboon model.
    Redl HR, Martin U, Khadem A, Pelinka LE, van Griensven M.
    Crit Care; 2005 Jul 21; 9(6):R735-44. PubMed ID: 16356222
    [Abstract] [Full Text] [Related]

  • 16. Prevalence of extended-spectrum beta-lactamase and class 1 integron integrase gene intl1 in Escherichia coli from Thai patients and healthy adults.
    Pongpech P, Naenna P, Taipobsakul Y, Tribuddharat C, Srifuengfung S.
    Southeast Asian J Trop Med Public Health; 2008 May 21; 39(3):425-33. PubMed ID: 18564681
    [Abstract] [Full Text] [Related]

  • 17. Oleuropein: a novel immunomodulator conferring prolonged survival in experimental sepsis by Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ, Geladopoulos T, Chrisofos M, Koutoukas P, Vassiliadis J, Alexandrou I, Tsaganos T, Sabracos L, Karagianni V, Pelekanou E, Tzepi I, Kranidioti H, Koussoulas V, Giamarellou H.
    Shock; 2006 Oct 21; 26(4):410-6. PubMed ID: 16980890
    [Abstract] [Full Text] [Related]

  • 18. Mechanisms of resistance and mobility among multidrug-resistant CTX-M-producing Escherichia coli from Canadian intensive care units: the 1st report of QepA in North America.
    Baudry PJ, Nichol K, DeCorby M, Lagacé-Wiens P, Olivier E, Boyd D, Mulvey MR, Hoban DJ, Zhanel GG.
    Diagn Microbiol Infect Dis; 2009 Mar 21; 63(3):319-26. PubMed ID: 19216943
    [Abstract] [Full Text] [Related]

  • 19. Role of host and bacterial virulence factors in Escherichia coli spontaneous bacterial peritonitis.
    Cereto F, Herranz X, Moreno E, Andreu A, Vergara M, Fontanals D, Roget M, Simó M, González A, Prats G, Genescà J.
    Eur J Gastroenterol Hepatol; 2008 Sep 21; 20(9):924-9. PubMed ID: 18794608
    [Abstract] [Full Text] [Related]

  • 20. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].
    Akyar I.
    Mikrobiyol Bul; 2008 Oct 21; 42(4):713-5. PubMed ID: 19149097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.